T1	Participants 123 156	patients with chronic hepatitis C
T2	Participants 340 408	patients with chronic hepatitis C and advanced fibrosis or cirrhosis
T3	Participants 194 268	Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial
T4	Participants 604 723	517 HALT-C patients received peginterferon alfa-2a (90 microg/week); 532 received no additional treatment for 3.5 years
T5	Participants 944 977	Patients with cirrhosis (n = 427)
